Insmed has come up short in its attempt to expand its newly approved potential blockbuster Brinsupri into a new indication. | ...

The deal with the U.K.’s Nuclear Decommissioning Authority runs for 15 years with an option to renew for a “potentially ...

Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

Within the mammoth defense bill, the Biosecure Act has the potential to raise new hurdles for certain life sciences companies ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

The Swedish drugmaker has come up short in its effort to push imlifidase into treatment of the autoimmune condition ...

After a long run of regulatory stumbles and the recent wit | "Following the withdrawal of Ocaliva from the U.S. market, we ...

As it kicks off a pivotal phase 3 trial of its investigational treatment for Angelman syndrome (AS), Ionis Pharmaceuticals is ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...